Category: Clinical Trial Watch

in Clinical Trial Watch

Really? They found that combining statins with drugs that inhibited cyclin-dependent protein kinase enzymes, which regulate and promote the cellular growth of cancer, produced a similar response with both RAS- and BRAF-mutated oncogenes. http://news.yale.edu/2012/12/13/yale-team-identifies-successful-combination-drug-therapies-melanoma-mutations

New Melanoma Treatment Might Delay Cancer Progression

—

by

SATURDAY, Sept. 29 (HealthDay News) — Researchers say they’ve discovered a two-drug combination that delays treatment resistance in patients with advanced melanoma. By targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said. Melanoma…

Glaxo Two-Drug Melanoma Combo Slows Cancer in Study

—

by

GlaxoSmithKline Plc (GSK)’s combination of two experimental melanoma medicines slowed the cancer’s progress longer than a single-drug treatment, a study found. Patients taking Glaxo’s dabrafenib and trametinib together delayed tumors from progressing for 9.4 months, compared with 5.8 months for patients taking dabrafenib alone, according to the study of 162 patients. The trial was part…

Methods to Improve Adoptive T-Cell Therapy for Melanoma: IFN-γ Enhances Anticancer Responses of Cell Products for Infusion

—

by

in T-cell Melanoma

Further development of adoptive T-cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) has the potential to markedly change the long-term prognosis of patients with metastatic melanoma, and modifications of the original protocol that can improve its clinical efficacy are highly desirable. In this study, we demonstrated that a high in vitro tumor reactivity of infusion…

Engineering the Immune System to Fight Melanoma

—

by

in Immunotherapy Melanoma

ScienceDaily (Oct. 1, 2012) — Loyola University Medical Center has launched the first clinical trial in the Midwest of an experimental melanoma treatment that genetically engineers a patient’s immune system to fight the deadly cancer. A batch of the immune system’s killer T cells will be removed from the patient and genetically modified in a…

New Melanoma Treatment Might Delay Cancer Progression

—

by

SATURDAY, Sept. 29 (HealthDay News) — Researchers say they’ve discovered a two-drug combination that delays treatment resistance in patients with advanced melanoma. By targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said. Melanoma…

Co-opting a killer virus peptide to combat cancer

—

by

in Immunotherapy Melanoma

Myxoma virus is a decidedly nasty customer, particularly if you’re a rabbit. Or, it turns out, a human melanoma cell. However, recent studies have shown the virus is not known to infect human cells, raising the prospect of conscripting it in the battle against skin cancer. That said, not everyone is going to be happy…

Dabrafenib + Trametinib Active in Metastatic Melanoma

—

by

MONDAY, Oct. 1 (HealthDay News) — For patients with metastatic melanoma with BRAF V600 mutations, combination therapy with a selective BRAF inhibitor (dabrafenib) and a mitogen-activated protein kinase inhibitor (trametinib) is tolerable and active, according to a study published online Sept. 29 in the New England Journal of Medicine to coincide with presentation at the…

Dual Kinase Therapy Slows BRAF Mutated Metastatic Melanoma

—

by